Fournier Wins Repaglinide Challenge
Executive Summary
Family-owned, mid-sized Fournier isn't the most obvious choice of marketing partner to help boost sales of Novo Nordisk's flagging oral antidiabetic repaglinide. But Fournier's renewed focus on metabolic disease, strong French and European presence and likely commitment to the drug may yet endorse Novo's choice.